Aurobindo Pharma shares jump after arm signs key deal to market biosimilars in EUAurobindo Pharma shares jump after arm signs key deal to market biosimilars in EU

Introduction

Leading Indian biosimilars company signs agreement with a European healthcare firm to market and distribute two EMA-approved biosimilars in select EU territories, including France and Germany.

Also Read: Waaree Energies approves ₹3,900 Cr capex for glass manufacturing facility; stock gains 3%

Share price movement of Aurobindo Pharma

On March 27, 2026, Aurobindo Pharma Ltd opened at ₹1,330.90, up 1.79% from its previous close of ₹1,307.70. The stock reached a high of ₹1,330.90 (1.79%) and a low of ₹1,296.40 (-0.86%). By 12:12 PM, it traded at ₹1,312.00, a 0.33% increase, with a market cap of ₹76,201.17 crore.

CuraTeQ Signs EU Biosimilars Deal

CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has signed a marketing and distribution agreement with STADA Arzneimittel AG. The deal covers select European Union territories, including France and Germany.

Under the agreement, STADA will market and distribute two EMA-approved biosimilars developed by CuraTeQ. New brand names will be registered for each biosimilar, aiming to expand market reach and revenue growth in EU markets.

Stock performance of Aurobindo Pharma for period of 1 week, 6 months, and 1 year

Aurobindo Pharma Ltd delivered a 1-week return of 1.27%, a 6-month return of 20.0%, and a 1-year return of 12.3%.

Also Read: HDFC Life receives ₹126 Cr tax demand, ₹45 Cr interest added

Shareholding pattern of Aurobindo Pharma

Particulars	Dec 2025	Sep 2025	Jun 2025
Promoter	51.80%	51.80%	51.80%
FII	14.00%	14.20%	14.40%
DII	27.70%	27.60%	26.90%
Public	6.60%	6.40%	6.90%

About Aurobindo Pharma

Aurobindo Pharma Ltd (NSE: AUROPHARMA) manufactures and markets active pharmaceutical ingredients, generic drugs, and related services, serving domestic and international markets with a diverse pharmaceutical portfolio.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs